摘要 : Is docetaxel (Taxotere; Aventis, Strasbourg, France) plus a corticosteroid a more efficacious regimen for hormone-refractory prostate cancer than the current standard of mitoxantrone (Novantrone?; OSI, Melville, NY) plus a cortico... 展开 Is docetaxel (Taxotere; Aventis, Strasbourg, France) plus a corticosteroid a more efficacious regimen for hormone-refractory prostate cancer than the current standard of mitoxantrone (Novantrone?; OSI, Melville, NY) plus a corticosteroid? The latter enhances quality of life and pain relief, but does not prolong survival. 收起